Brose McVey is leading a new health care clinic company that is squarely aimed at helping individuals, the self-employed and even large businesses deal with the new health care reality that is emerging under Obamacare.
A San Diego venture capital firm has made a big bet on Indigo BioSystems Inc., which just installed its founder as the new chief executive.
While the biggest hospital profit margins are made in the suburbs, the biggest pile of cash—$353 million in 2012—is made at the three downtown campuses run by Indiana University Health. In fact, those hospitals generated 32 percent of all operating gains posted by central Indiana hospitals in 2012.
Two new studies show that Americans have every economic incentive to consume too much food and then, when that overeating creates health problems for them, to consume lots of health care to fix it.
Indiana ranks 10th in the nation for the highest spending on health care and 10th in the nation for the number of adults missing six or more teeth. That’s not a coincidence. Hoosiers do a poor job of taking care of themselves, and we end up paying for it in higher taxes and health insurance premiums.
Radiopharmaceuticals maker Zevacor Molecular plans to open a $40 million isotope-production facility in Noblesville, creating nearly 50 good-paying jobs within five years.
RANAC Corp., a small firm in Indianapolis, cut its spending on health benefits 25 percent after dropping its group health plan. Could it be a sign of things to come?
Takeda Pharmaceutical Co. executives covered up the cancer risks of its diabetes medicine Actos to protect billions of dollars in sales, a lawyer for two women argued.
Gov. Pence's HIP 2.0 plan is nothing less than an attempt to roll back liberal policy on low-income health benefits as far as currently possible–and to get other states to follow suit. It might even be an opening bid for president.
Fees on hospitals will generate the lion’s share of the funds for Gov. Mike Pence’s Healthy Indiana Plan expansion. But the benefits hospitals will receive will outweigh those costs.
Now that Indianapolis-area hospitals employ large numbers of physicians, a new study suggests the integrated health systems will be able to charge higher prices to private health insurers.
An Indianapolis-based biotech company plans to use $2.75 million in new funding to begin commercial production of its algae-based nutritional supplements, the firm announced Monday.
The 274-131 vote follows calls to restore the credit by a coalition of companies including Indianapolis-based Eli Lilly and Co. and Texas Instruments Inc.
On the eve of Obamacare, almost no central Indiana hospitals were having trouble making money. Hip replacements, heart surgery and Hamilton County were the biggest drivers of profits.
Attempts to build the sector are making headway, but Indiana still lags leading states.
When I predicted on March 13 that Obamacare would fail to expand individual private insurance coverage in Indiana, I was completely off. It now looks like an extra 30,000 Hoosiers have bought individual health insurance this year.
The news this morning couldn’t have been worse for Endocyte Inc. But if it had to come, the timing couldn’t have been better–because it allowed Endocyte to raise a pile of cash to spend on the other drugs in its pipeline.
Endocyte Inc.’s stock fell more than 60 percent in early trading Friday after the drug it’s developing with Merck & Co.’s backing failed to help patients in a trial for ovarian cancer.
The envisioned 26-acre, $200-million-or-more complex would bridge IU’s School of Medicine with the city’s life sciences firms, including those at the nascent 16 Tech, a business park.
A new report from the Commonwealth Fund provides plenty to criticize everyone involved in health care in Indiana: It shows health care costs run higher in Indiana than the rest of the country while patients’ health and the quality of health care providers in some key areas are worse.
